EQS-News: GeoVax, Inc. / Key word (s): Financial GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial 15.01.2025 / 15:05 CET/CEST The issuer is solely responsible for the content ...

Eligible patients were concurrently randomly assigned 1:1 to receive nivolumab (3 mg/kg once every 2 weeks; three cycles) plus ipilimumab (1 mg/kg; one dose at cycle 1 only) or platinum-doublet ...

Neoadjuvant SHR-A1811 showed similar pathologic complete response rates to the standard 4-drug regimen in patients with ...

Survival according to treatment group and complete pathologic response (pT0) in patients treated with either neoadjuvant MVAC and cystectomy or cystectomy alone. Hazard ratios for subgroups ...

In the rapidly evolving field of cancer treatment, international collaboration has been crucial in addressing complex ...

Neoadjuvant chemotherapy followed by transoral robotic surgery (NECTORS) and neck dissection led to better survival outcomes ...

Published in Clinical Cancer Research, results of a VHIO-led study underscore the potential of the RAD51 biomarker in ...

However, their efficacy in neoadjuvant therapy remains uncertain. Case presentation: We report the case of a 68-year-old male diagnosed with HNSCC who received neoadjuvant nivolumab (anti-PD-1 ...

Neoadjuvant patritumab deruxtecan (HER3-DXd) alone or with letrozole achieved similar pathologic complete response (pCR) rate and overall response rate (ORR ...

A new study published in the journal of Cancer Medicine found that in patients with breast cancer undergoing neoadjuvant ...